EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBITLicense, Supply and Distribution Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • Delaware
THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made as of March 6, 2019 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. a Nevada corporation and ELITE LABORATORIES, INC., Delaware corporation located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”), and LANNETT COMPANY, INC., USA, a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“LANNETT”).
EX-10.208 2 dex10208.htm FORM OF LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT EXECUTION COPYLicense, Supply and Distribution Agreement • May 5th, 2020 • New York
CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION
EXHIBIT 10.34 LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT (the "Agreement"), made effective this 6th day of January, 1997 ("Effective Date"), by and between SHERWOOD MEDICAL COMPANY, a corporation...License, Supply and Distribution Agreement • April 8th, 1998 • Innerdyne Inc • Services-commercial physical & biological research • California
ContractLicense, Supply, and Distribution Agreement • March 7th, 2024 • Evolus, Inc. • Pharmaceutical preparations • England and Wales
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.
September 20, 2021License, Supply and Distribution Agreement • June 29th, 2022 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SECOND AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • March 14th, 2007 • Curagen Corp • Services-commercial physical & biological research
THIS SECOND AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made and entered into as of this 24th day of October, 2006 (Effective Date) by and between F.Hoffmann-La Roche Ltd. (“FHLR”) having a principal office at Grenzacherstrasse 124, Basel, Switzerland and 454 Life Sciences Corporation (“454”) having a principal office at 20 Commercial Street, Branford, CT 06405, USA.
Contacts: Deborah Carty Mark Vincent NexMed, Inc. Euro RSCG Life NRP 609-208-9688, ext: 159 (212) 845-4239 dcarty@nexmed.com Mark.Vincent@eurorscg.comLicense, Supply and Distribution Agreement • July 6th, 2004 • Nexmed Inc • Pharmaceutical preparations
Robbinsville, NJ, July 6, 2004 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the NexACT(R) drug delivery technology, today announced that it has entered into a license, supply and distribution agreement with Schering AG, Germany (FSE: SCH, NYSE: SHR). This agreement provides Schering with exclusive commercialization rights to Alprox-TD(R) in Europe, Russia, the Middle East, South Africa, Australia and New Zealand. NexMed will retain the intellectual property relating to Alprox-TD(R) and will manufacture and supply the product to Schering. Under the terms of this partnership, NexMed will receive future milestone payments as well as a share of the revenue through transfer price payments based on the supply of Alprox-TD(R). The overall financial terms are intended, depending upon performance levels, to approximate an equal sharing of the value of the product.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDLicense, Supply and Distribution Agreement • June 14th, 2021 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of July 29, 2019 (the “Amendment”), by and between Elite Pharmaceuticals, Inc., a Nevada corporation and Elite Laboratories, Inc., a Delaware corporation with offices at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively “Elite”) and Lannett Company, Inc., a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“Lannett”) (and together the “Parties”) relating to that License, Supply and Distribution Agreement between the Parties dated March 6, 2019 (the “Agreement”);
LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • August 13th, 2007 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • Delaware
This License, Supply and Distribution Agreement (this “Agreement”) is made and entered into as of August 6, 2007, by and between Senetek PLC, a United Kingdom public company with its offices located at 831 Latour Court, Napa, California 94558 (“Senetek”), and Triax Aesthetics, LLC, a Delaware limited liability company with its offices located at 20 Commerce Drive, Cranford, New Jersey 07016(“Licensee”).
License, SUPPLY and Distribution Agreement Elite pharmaceuticals, inc., elite laboratories, inc.,License, Supply and Distribution Agreement • June 14th, 2018 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New York
THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made as of May 22, 2018 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. and ELITE LABORATORIES, INC., Nevada corporations located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”), and GLENMARK PHARMACEUTICALS INC., USA, a Delaware corporation located at 750 Corporate Drive, Mahwah, New Jersey 07430 (“GLENMARK”).
LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • August 5th, 2005 • Curagen Corp • Services-commercial physical & biological research • New York
WHEREAS, 454 and FHLR (the “Parties”) desire to have 454 manufacture and supply to FHLR certain products and to have FHLR manufacture, distribute and sell certain products under the terms and conditions stated herein.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. FIRST AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT...License, Supply and Distribution Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of August 1, 2018 (the “Amendment”), by and between Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”) and Glenmark Pharmaceuticals Inc. USA, a Delaware corporation located at 750 Corporate Drive, Mahwah, New Jersey 07430 (“Glenmark”) relating to that License, Supply and Distribution Agreement Between Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.) and Glenmark dated May 22, 2018 (the “Agreement”);
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. FIRST AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • March 14th, 2007 • Curagen Corp • Services-commercial physical & biological research
THIS FIRST AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made and entered into as of this 19th day of December, 2005 (“Effective Date”) by and between F.Hoffmann-La Roche Ltd. (“FHLR”) having a principal office at Grenzacherstrasse 124, Basel, Switzerland and 454 Life Sciences Corporation (“454”) having a principal office at 20 Commercial Street, Branford, CT 06405, USA.
September 20, 2021 Lannett Company, Inc.License, Supply and Distribution Agreement • June 29th, 2022 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTHLicense, Supply and Distribution Agreement • June 29th, 2022 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • Delaware
THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made as of July 20, 2021 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. a Nevada corporation and ELITE LABORATORIES, INC., a Delaware corporation located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”), and LANNETT COMPANY, INC., USA, a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“LANNETT”).
1 EXHIBIT 10.8 AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • August 16th, 1999 • Minimed Inc • Orthopedic, prosthetic & surgical appliances & supplies
WITNESSETH:License, Supply and Distribution Agreement • November 9th, 2004 • Nexmed Inc • Pharmaceutical preparations
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDLicense, Supply and Distribution Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of January 2, 2020 (the “Amendment”), by and between Elite Laboratories, Inc., a Delaware corporation, and Elite Pharmaceuticals, Inc., a Nevada corporation, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”) and Glenmark Pharmaceuticals Inc. USA, a Delaware corporation located at 750 Corporate Drive, Mahwah, New Jersey 07430 (“Glenmark”) relating to that License, Supply and Distribution Agreement Between Elite and Glenmark dated May 22, 2018 and the Second Amendment to the License, Supply and Distribution Agreement dated August 1, 2018 (together the “Agreement”);
CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS (*) DENOTE SUCH OMISSIONS. LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • August 9th, 2004 • Praecis Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT is made the April 27, 2004 (the “Effective Date”) by and between PRAECIS PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of State of Delaware having its principal place of business at 830 Winter Street, Waltham, MA 02451, USA (hereinafter referred to as “Praecis”) and SCHERING AG, a corporation organized and existing under the laws of Germany having its principal place of business at 13442 Berlin, Germany (hereinafter referred to as “Schering”). Praecis and Schering are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT BETWEEN ELI LILLY AND COMPANY "Lilly" AND MINIMED INC. "MiniMed"License, Supply and Distribution Agreement • August 16th, 1999 • Minimed Inc • Orthopedic, prosthetic & surgical appliances & supplies • Indiana
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. THIRD AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENTLicense, Supply and Distribution Agreement • March 14th, 2007 • Curagen Corp • Services-commercial physical & biological research
THIS THIRD AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made and entered into as of this 19th day of December, 2006 (Effective Date) by and between F.Hoffmann-La Roche Ltd. (“FHLR”) having a principal office at Grenzacherstrasse 124, Basel, Switzerland and 454 Life Sciences Corporation (“454”) having a principal office at 20 Commercial Street, Branford, CT 06405, USA.
